Online inquiry

IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10426MR)

This product GTTS-WQ10426MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Ankylosing spondylitis (AS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ10426MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1215MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ7139MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ12597MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ1104MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ11092MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ12081MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MOR-00208
GTTS-WQ10600MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY3300054
GTTS-WQ14544MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SAR156597
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW